Genmab — Juni 2018
-
BRISTOL-MYERS SQUIBB: U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma https://americanpharmacynews.com/stories/511445167-bristol-myers-squibb-u-s-food-and-drug-administration-lifts-partial-clinical-hold-on-opdivo-nivolumab-based-combination-study-in-multiple-myeloma
-
Tror bare det virker ekstra risikabelt nu hvor vi har fået én skuffelse som markedet straffede hårdt, så psykologisk set virker det bare endnu mere risikabelt, men det er nok bare fordi man ikke selv er helt klar over risikoen. Går det godt vil vi jo alle sige det var et genialt træk
-
you can not start a trial with 100% certainty of success unfortunately. you have to take risk. Personally. I believe the Dara franchise is worth much more as todays price reflects, as discussed many times before, so whatever is extra is great. Even if TV fails, at some point we should still go up significantly
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind